Pegbio Co., Ltd. (2565)

Overview

Pegbio Co., Ltd. is a forward-thinking biotechnology company that excels in the in-house discovery and advancement of groundbreaking therapies. The company concentrates on developing peptide and small molecule drugs aimed at treating chronic diseases, with a notable emphasis on metabolic disorders. Pegbio's areas of specialization include conditions such as type 2 diabetes, obesity, non-alcoholic steatohepatitis, and rare endocrine disorders like congenital hyperinsulinemia. The firm is strategically positioned to leverage the growing demand for innovative treatments for chronic diseases alongside the latest innovations in biologic drug technologies. Pegbio's comprehensive development pipeline showcases its commitment to expanding treatment options for patients suffering from lifestyle-related and metabolic disorders through enhanced therapeutic agents.

Products and Services

• PB-119: This long-acting glucagon-like peptide-1 (GLP-1) receptor agonist is designed to improve glycemic control and facilitate weight management. PB-119 represents a core innovation in Pegbio's product lineup, aiming to effectively address the challenges faced by patients with type 2 diabetes and obesity.
• Peptide Engineering: Pegbio employs advanced technology in polyethylene glycol (PEG) modification to enhance the stability and efficacy of its therapeutic agents. The company's proprietary peptide engineering techniques are pivotal in creating innovative solutions tailored for chronic disease management.
• Pipeline for Metabolic Disorders: Pegbio’s diverse development pipeline includes additional candidates targeting gout, opioid-induced constipation, and other related metabolic ailments. These products expand the company's portfolio and reaffirm its commitment to addressing various chronic conditions linked to metabolic health.